# A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

> **NCT07469488** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 122 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- VTE (Venous Thromboembolism)
- Rash Due to Epidermal Growth Factor Receptor Inhibitors
- Infusion Reaction

## Interventions

- **COMBINATION_PRODUCT:** Enhanced dermatologic management
- **COMBINATION_PRODUCT:** Enhanced IRR Prophylaxis
- **COMBINATION_PRODUCT:** Enhanced VTE Prophylaxis (Cohort 1 only)

## Key facts

- **NCT ID:** NCT07469488
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-08-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07469488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07469488, "A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07469488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*